Production (Stage)
IGC Pharma, Inc.
IGC
$0.3808
-$0.0342-8.24%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.50% | 1.64% | -11.98% | -15.38% | 47.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.50% | 1.64% | -11.98% | -15.38% | 47.48% |
| Cost of Revenue | 6.54% | 1.52% | -30.93% | -39.86% | 30.21% |
| Gross Profit | -15.55% | 1.76% | 11.95% | 15.50% | 65.84% |
| SG&A Expenses | -40.75% | -32.59% | -14.09% | -14.52% | -13.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.35% | -21.68% | -9.32% | -3.68% | -6.02% |
| Operating Income | 29.02% | 24.10% | 9.00% | 2.35% | 10.18% |
| Income Before Tax | 45.22% | 37.72% | -16.33% | -23.22% | -12.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.22% | 37.72% | -16.33% | -23.22% | -12.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.22% | 37.72% | -16.33% | -23.22% | -12.98% |
| EBIT | 29.02% | 24.10% | 9.00% | 2.35% | 10.18% |
| EBITDA | 30.70% | 25.47% | 9.48% | 2.44% | 10.61% |
| EPS Basic | 56.69% | 50.04% | 7.21% | -3.04% | 1.05% |
| Normalized Basic EPS | 46.46% | 40.14% | 27.59% | 17.16% | 19.97% |
| EPS Diluted | 56.69% | 50.04% | 7.21% | -3.04% | 1.05% |
| Normalized Diluted EPS | 46.46% | 40.14% | 27.59% | 17.16% | 19.97% |
| Average Basic Shares Outstanding | 30.04% | 29.68% | 29.64% | 20.66% | 12.10% |
| Average Diluted Shares Outstanding | 30.04% | 29.68% | 29.64% | 20.66% | 12.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |